Suchergebnisse - "Halpin, David M G"

PubPharm (14)

1

A Response to : Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"

enthalten in: Advances in therapy | 2023

von Ismaila, A. | Haeussler, K. | Malmenäs, M. | +5

CommentOn: Adv Ther. 2022 Sep;39(9):3957-3978. - PMID 35849317

2

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease : Post hoc analysis of the IMPACT trial

enthalten in: Respirology (Carlton, Vic.) | 2022

von Thompson, P. | Criner, G. | Dransfield, M. | +9

CommentIn: Respirology. 2022 Dec;27(12):1006-1007. - PMID 36031687

3

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD : IMPACT trial post hoc analysis

enthalten in: Respiratory medicine | 2022

von Bardsley, S. | Criner, G. | Halpin, D. | +12

4

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease : A Network Meta-Analysis

enthalten in: Advances in therapy | 2022

von Ismaila, A. | Haeussler, K. | Czira, A. | +11

ErratumIn: Adv Ther. 2022 Sep 2;:. - PMID 36056291

5

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD : A Network Meta-Analysis

enthalten in: Advances in therapy | 2022

von Ismaila, A. | Haeussler, K. | Czira, A. | +10

CommentIn: Adv Ther. 2023 May;40(5):2549-2555. - PMID 37004641

6

Single-Inhaler Triple Therapy in Patients with Advanced COPD : Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial

enthalten in: International journal of chronic obstructive pulmonary disease | 2022

von Gabrio, A. | Gunsoy, N. | Baio, G. | +12

7

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population : The INTREPID Trial

enthalten in: International journal of chronic obstructive pulmonary disease | 2022

von Halpin, D. | Kendall, R. | Shukla, S. | +9

8

InforMing the PAthway of COPD Treatment (IMPACT) trial : fibrinogen levels predict risk of moderate or severe exacerbations

enthalten in: Respiratory research | 2021

von Singh, D. | Criner, G. | Dransfield, M. | +12

9

Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD : A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial

enthalten in: Chest | 2021

von Hanania, N. | Mannino, D. | Criner, G. | +12

CommentIn: Chest. 2021 Mar;159(3):895-896. - PMID 33678268

10

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD : results on cardiovascular safety from the IMPACT trial

enthalten in: Respiratory research | 2020

von Day, N. | Kumar, S. | Criner, G. | +13